1. SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years. (12th June 2018) Authors: Wollenhaupt, J.; Silverfield, J.; Lee, E. B.; Terry, K.; Kwok, K.; Strengholt, S.; DeMasi, R.; Wang, L. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 978 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0174 Analysis of Non-melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Programme. (9th June 2015) Authors: Curtis, J.; Lee, E.B.; Martin, G.; Mariette, X.; Terry, K.; Chen, Y.; Geier, J.; Andrews, J.; Kaur, M.; Fan, H.; Nduaka, C. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗